Literature DB >> 11072043

Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin.

R E Sheridan1, S S Deshpande, P Amersdorfer, J D Marks, T Smith.   

Abstract

The neutralization of botulinum toxin serotype A with polyclonal equine antitoxin was studied in isolated mouse hemidiaphragms and compared to the same action in live mice. The biological activity of the toxin in the isolated muscle could be markedly reduced with excess antitoxin, estimated as 3:1 molar ratios of IgG Ab:toxin or better. Toxin neutralization in vivo required higher ratios of Ab:toxin, ranging from 30:1 at high toxin doses and increasing to 100:1 at 10xLD50 toxin. At equimolar Ab to toxin ratios in the isolated muscle, the biological activity of the toxin underwent a statistically significant increase. This paradoxical effect of the polyclonal antisera was serotype selective and independent of the presence or absence of hemagglutinin in the toxin. The enhancement of toxin activity was subsequently localized to occupancy of one of four epitopes on the toxin using monoclonal antibodies to mimic the effect of the antitoxin. The enhancement of toxin activity suggests that botulinum toxin may undergo a conformational change upon binding antibodies to certain domains. This phenomenon could contribute to the observed concentration dependent changes in neutralization efficacy with antitoxin in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11072043     DOI: 10.1016/s0041-0101(00)00189-6

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  6 in total

1.  Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.

Authors:  Christelle Mazuet; Julie Dano; Michel R Popoff; Christophe Créminon; Hervé Volland
Journal:  PLoS One       Date:  2010-08-26       Impact factor: 3.240

2.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

3.  Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies.

Authors:  Suzanne R Kalb; Wanda I Santana; Isin N Geren; Consuelo Garcia-Rodriguez; Jianlong Lou; Theresa J Smith; James D Marks; Leonard A Smith; James L Pirkle; John R Barr
Journal:  BMC Biochem       Date:  2011-11-15       Impact factor: 4.059

4.  Efficacy of equine botulism antitoxin in botulism poisoning in a guinea pig model.

Authors:  Andrew Emanuel; Hongyu Qiu; Douglas Barker; Teresa Takla; Karen Gillum; Nancy Neimuth; Shantha Kodihalli
Journal:  PLoS One       Date:  2019-01-11       Impact factor: 3.240

Review 5.  Passive antibody administration (immediate immunity) as a specific defense against biological weapons.

Authors:  Arturo Casadevall
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

6.  Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Yvonne Liu; Siham Chahboun; Thibaut Pelat; Arnaud Avril; André Frenzel; Thomas Schirrmann; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  MAbs       Date:  2014-01-09       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.